Latest Blogs

Jun 19, 2019
"We believe what mattered the most about #ASCO19 is that patients were part of the discussion," write Dr. Mark A. Lewis and Dr. Chadi Nabhan.
Jun 11, 2019
I am excited about the entire Breakthrough program, including a session I am leading on the impact of social media and telehealth on cancer care.
Jun 11, 2019
Real actions that promote women and under-represented groups in medicine are doable, starting today.
Jun 07, 2019
"Oncologists are asked every day to peer into a crystal ball and speak sagely about how much time is left," writes Dr. Mark A. Lewis, "...but each person with cancer enters an irreproducible experiment in which they are the sole participant."
Subscribe to this column

Clifford A. Hudis, MD, FACP, FASCO

Clifford A. Hudis, MD, FACP, FASCO, is the CEO of ASCO. Prior to this role, he served as Chief of the Breast Medicine Service and an attending physician at Memorial Sloan Kettering Cancer Center and as a professor in the Department of Medicine at Weill Cornell Medical College. He is a Past President of ASCO. His research interests include all areas of care related to breast cancer, with a focus on the development of novel systemic therapies and prevention interventions related to the obesity and inflammation. Follow Dr. Hudis on Twitter @CliffordHudis.

May 20, 2019
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
Mar 26, 2019
Dr. Sharpless joined me to talk about pediatric cancer research, clinical trial methodology, eligibility criteria, and more.
Mar 11, 2019
For many of us not a day has gone by without some reminder of Arti, but last week brought it all back into sharp focus as I was asked to talk about the role we at ASCO played in her career during a symposium in her honor.
Feb 07, 2019
Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.
Feb 01, 2019
What will each of us do, going forward, to further confront and reduce the global burden of cancer? For us at ASCO, the challenge will be answered through our mission pillars: education, research, and quality.
Jan 28, 2019
Editor’s note: Dr. Hudis hosts the ASCO in Action Podcast, which focuses on policy and practice issues affecting providers and patients. An excerpt of a recent episode is shared below; it has been edited for length and clarity.

Pages